Imagine snapping a photo of your favorite object, a vintage car, a family heirloom, or even your pet, and instantly transforming it into a lifelike 3D model. Thanks to Meta’s SAM 3D, this futuristic ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...

Researchers at Karolinska Institutet and KTH have developed a computational method that can reveal how cells change and specialize in the body. The study, which has been published in the journal PNAS, ...

Instagram is introducing a new tool that lets you see and control your algorithm, starting with Reels, the company announced on Wednesday. The new tool, called “Your Algorithm,” lets you view the ...

Users can note which content they would like to view more frequently. Instagram is handing users some control in deciding what content they see. The social media giant is allowing users to have a say ...

A paper co-authored by Prof. Alex Lew has been selected as one of four "Outstanding Papers" at this year's Conference on Language Modeling (COLM 2025), held in Montreal in October. Lew and his ...

Modern consumer brands are confronting an uncomfortable truth: the products they once made for retail shelves often fail online. The search behavior, recommendation engines, AI assistants, and ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...

Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically ...

– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...